4//SEC Filing
Valeant Pharmaceuticals International, Inc. 4
Accession 0000885590-13-000041
$BHCCIK 0000885590operating
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 9:22 PM ET
Size
9.5 KB
Accession
0000885590-13-000041
Insider Transaction Report
Form 4
STEVENSON KATHARINE BERGHUIS
Director
Transactions
- Award
Common Stock, no par value
2013-05-30+3,225→ 26,705 total - Tax Payment
Common Stock, no par value
2013-05-30$90.81/sh−3,873$351,707→ 22,833 total - Disposition to Issuer
Deferred Share Units
2013-05-30−3,225→ 0 totalExercise: $0.00→ Common Shares, no par value (3,225 underlying)
Footnotes (3)
- [F1]On May 30, 2012, upon recommendation of the Nominating and Corporate Governance Committee, the Board determined that it was in the Company's best interest to terminate the equity program of the Mandatory Share Units (other units granted prior to October 3, 2004) and to be delivered in 2013 pursuant to the plan termination rules under Code Section 409A. The unit disposed of here may have previously have been settled for one share of issuer common stock or the cash value, thereof, depending on the terms of the applicable award. The prior deferred share units have been exchanged for an equal amount of common shares.
- [F2]This number represents common shares purchased and other equity awards that were previously reported in Table 1.
- [F3]This number represents common shares withheld to satisfy certain tax withholding obligations due upon settling of Mandatory Share Units.
Documents
Issuer
Valeant Pharmaceuticals International, Inc.
CIK 0000885590
Entity typeoperating
IncorporatedNJ
Related Parties
1- filerCIK 0000885590
Filing Metadata
- Form type
- 4
- Filed
- Jun 2, 8:00 PM ET
- Accepted
- Jun 3, 9:22 PM ET
- Size
- 9.5 KB